Overview

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This open label comparison study examines the hypothesis that teriparatide given immediately following repair of an atypical subtrochanteric or diaphyseal femoral shaft fracture will enhance healing and improve bone mineral density compared to delayed treatment (after six months) with teriparatide or no treatment with teriparatide (patients who refuse therapy or for whom teriparatide is contraindicated). Patients with up-front teriparatide in addition will have greater quality of life measures and less pain compared to those with delayed or no therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Susan L. Greenspan
University of Pittsburgh
Collaborators:
Eli Lilly and Company
University of Pittsburgh
Treatments:
Teriparatide